ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Expert Review of Neurotherapeutics

• Publication date

  2016-04-25

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1080/14737175.2016.1174577PMID 27042868
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial.

  2016cited by this paper
• Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial.

  2015cited by this paper
• Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder

  2015cited by this paper
• Cardiovascular and cerebrovascular risk factors and events associated with second‐generation antipsychotic compared to antidepressant use in a non‐elderly adult sample: results from a claims‐based inception cohort study

  2015cited by this paper
• ITI-007 demonstrates brain occupancy at serotonin 5-HT2A and dopamine D2 receptors and serotonin transporters using positron emission tomography in healthy volunteers

  2015cited by this paper
• A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia.

  2015cited by this paper
• Poster #S78 THE NOVEL PHARMACOLOGY OF ITI-007 IS ENHANCED AND EXTENDED BY ITS METABOLIC BACK CONVERSION FROM IC200131

  2014cited by this paper
• Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia

  2014cited by this paper
• Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission

  2014cited by this paper
• Emerging drugs for schizophrenia: an update

  2014cited by this paper
• Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.

  2014cited by this paper
• Reviewing the ketamine model for schizophrenia

  2014cited by this paper
• Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.

  2013influential reference
• Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia.

  2013cited by this paper
• 5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders

  2013cited by this paper
• Non‐adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies

  2013cited by this paper
• Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study.

  2013cited by this paper
• Antipsychotic-Induced Metabolic and Cardiovascular Side Effects in Schizophrenia: A Novel Mechanistic Hypothesis

  2013cited by this paper
• Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo.

  2013cited by this paper
• Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration.

  2012cited by this paper
• Metabolic and cardiovascular adverse effects associated with antipsychotic drugs

  2012cited by this paper
• Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it?

  2012influential reference
• Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010.

  2012cited by this paper
• A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.

  2012cited by this paper
• Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

  2012cited by this paper
• Serotonin 2A receptor antagonists for treatment of schizophrenia

  2011cited by this paper
• Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study.

  2011cited by this paper
• What are we looking for in new antipsychotics?

  2011cited by this paper
• Antipsychotic drugs and obesity.

  2011cited by this paper
• Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach.

  2011cited by this paper
• Past and present progress in the pharmacologic treatment of schizophrenia.

  2010cited by this paper
• From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics

  2010cited by this paper
• Increased serotonin 2A receptor availability in the orbitofrontal cortex of physically aggressive personality disordered patients.

  2010cited by this paper
• PAGES_DCNS 46_5.qxd:DCNS#45

  2010cited by this paper
• Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.

  2009cited by this paper
• Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis.

  2009cited by this paper
• The dopamine hypothesis of schizophrenia: version III--the final common pathway.

  2009cited by this paper
• Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials.

  2007cited by this paper
• Balancing Efficacy and Safety in Treatment with Antipsychotics

  2007cited by this paper
• Diretrizes da Federação Mundial das Sociedades de Psiquiatria Biológica para o tratamento biológico da esquizofrenia. Parte 2: tratamento de longo prazo

  2006cited by this paper
• Modern antipsychotic drugs: a critical overview

  2005cited by this paper
• World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Acute treatment of schizophrenia

  2005cited by this paper
• Clozapine Potentiation of N-Methyl-d-aspartate Receptor Currents in the Nucleus Accumbens: Role of NR2B and Protein Kinase A/Src Kinases

  2005cited by this paper
• A systematic review of atypical antipsychotic drugs in schizophrenia.

  2003cited by this paper
• Synergistic Action of 5-HT2A Antagonists and Selective Serotonin Reuptake Inhibitors in Neuropsychiatric Disorders

  2003cited by this paper
• Assessing positive and negative symptoms in outpatients with schizophrenia and mood disorders.

  2000cited by this paper
• The Role of Serotonin in Antipsychotic Drug Action

  1999cited by this paper
• Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia

  1999cited by this paper
• Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.

  1999cited by this paper
• Impulsive Aggression in Personality Disorder Correlates with Platelet 5-HT2A Receptor Binding

  1997cited by this paper
• Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile.

  1996cited by this paper
• Neuroleptics and the natural course of schizophrenia.

  1991cited by this paper
• Role of serotonin in the action of atypical antipsychotic drugs.

  1990cited by this paper
• Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons.

  1975cited by this paper

• Efficacy and Tolerability of Lumateperone in Acute Bipolar Depression: A Systematic Review and Meta-analysis

  2026cites this paper
• Volumetric absorptive microsampling for lumateperone analysis: method validation and stability evaluation

  2025cites this paper
• Efficacy and Safety of Cariprazine, Asenapine, Xanomeline–Trospium, and Lumateperone for Acute Exacerbations of Schizophrenia in Adults: A Network Meta-Analysis

  2025cites this paper
• Efficacy of Lumateperone in depression associated with bipolar II disorder: a pooled analysis of late-phase clinical trials

  2025cites this paper
• Dose-response efficacy and safety of lumateperone in bipolar depression: A preliminary meta-analysis of randomized controlled trials

  2025cites this paper
• Lumateperone monotherapy for major depressive episodes associated with bipolar disorder: efficacy and safety in a randomized placebo-controlled trial

  2025cites this paper
• Long-term safety and tolerability of lumateperone 42 mg in patients with bipolar disorder: results from a 6-month open-label extension study

  2025cites this paper
• Efficacy and safety of adjunctive therapy with lumateperone in major depressive disorder: a randomized-, double-blind, placebo-controlled clinical trial.

  2025cites this paper
• Application of the quality by design (QbD) approach to the development and validation of analytical methods for the quantification of Lumateperone Tosylate as the bulk drug and capsule dosage form by HPLC

  2025cites this paper
• IUPHAR Review - Novel therapeutic targets for schizophrenia treatment: a translational perspective.

  2025cites this paper
• Synthesis of anti-depressant molecules via metal-catalyzed reactions: a review

  2024cites this paper
• Exploring the Pharmacological and Clinical Features of Lumateperone: A Promising Novel Antipsychotic

  2024cites this paper
• Unlocking the potential of lumateperone and novel anti-psychotics for schizophrenia

  2024influential citation
• Efficacy and safety of lumateperone for bipolar depression and schizophrenia: a systematic review and meta-analysis

  2024cites this paper
• Advances in Mood Disorder Pharmacotherapy: Evaluating New Antipsychotics and Mood Stabilizers for Bipolar Disorder and Schizophrenia

  2024cites this paper
• Analysis of lumateperone data for patients with schizophrenia using related adverse events from the FDA adverse reporting system

  2024cites this paper
• Metabolic profiling of lumateperone in vitro and in vivo by UPLC-Q Exactive Orbitrap HRMS, and its pharmacokinetic study in rat plasma by LC-MS/MS.

  2024cites this paper
• Pharmacodynamic properties of lumateperone and its efficacy in acute bipolar depression: a mechanistic hypothesis based on data.

  2024cites this paper
• Adjunctive lumateperone (ITI‐007) in the treatment of bipolar depression: Results from a randomized placebo‐controlled clinical trial

  2023cites this paper
• The Novel Antipsychotic Lumateperone (Iti-007) in the Treatment of Schizophrenia: A Systematic Review

  2023influential citation
• The CANMAT and ISBD Guidelines for the Treatment of Bipolar Disorder: Summary and a 2023 Update of Evidence.

  2023cites this paper
• A review: FDA-approved fluorine-containing small molecules from 2015 to 2022.

  2023cites this paper
• Evaluating lumateperone for its use in treating depressive episodes associated with bipolar I or II disorder in adults

  2023cites this paper
• Towards Novel Potential Molecular Targets for Antidepressant and Antipsychotic Pharmacotherapies

  2023cites this paper
• The efficacy of lumateperone on symptoms of depression in bipolar I and bipolar II disorder: Secondary and post hoc analyses.

  2023cites this paper
• Lumateperone-mediated effects on prefrontal glutamatergic receptor-mediated neurotransmission: A dopamine D1 receptor dependent mechanism.

  2022cites this paper
• Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia

  2022cites this paper
• Recent Advances in Psychopharmacology

  2022cites this paper
• Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia

  2022influential citation
• Experimental Serotonergic Agents for the Treatment of Schizophrenia

  2021cites this paper
• Safety and tolerability of lumateperone 42 mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia.

  2021cites this paper
• New Antipsychotic Medications in the Last Decade

  2021cites this paper
• New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side-effect profile relative to established antipsychotics

  2021influential citation
• Lumateperone for major depressive episodes in bipolar I or bipolar II disorder

  2021cites this paper
• Lumateperone tosylate, A Selective and Concurrent Modulator of Serotonin, Dopamine, and Glutamate, in the Treatment of Schizophrenia.

  2021cites this paper
• Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial.

  2021cites this paper
• The role of lumateperone in the treatment of schizophrenia

  2021cites this paper
• Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets

  2021cites this paper
• Newer antipsychotics: Brexpiprazole, cariprazine, and lumateperone: A pledge or another unkept promise?

  2021cites this paper
• Fluorine-containing drugs approved by the FDA in 2019

  2020cites this paper
• Efficacy and Safety of Lumateperone for Treatment of Schizophrenia

  2020cites this paper
• Treatment possibilities of pharmaco-resistant schizofrenie in common clinical practice

  2020cites this paper
• Lumateperone for the Treatment of Schizophrenia.

  2020cites this paper
• Lumateperone: A Novel Antipsychotic for Schizophrenia

  2020cites this paper
• Evidence On The New Drug Lumateperone (Iti-007) For Psychiatric And Neurological Disorders.

  2020cites this paper
• Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities

  2019cites this paper
• Keeping up with the clinical advances : schizophrenia

  2019cites this paper
• Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone.

  2019cites this paper
• An evaluation of lumateperone tosylate for the treatment of schizophrenia

  2019cites this paper
• Serotonin Receptors for Treatment of Insomnia

  2019cites this paper
• Novel treatment possibilities in depression and schizophrenia

  2018cites this paper
• Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia

  2018cites this paper
• Investigational dopamine antagonists for the treatment of schizophrenia

  2017cites this paper
• Novel treatment options in depression and psychosis

  2017cites this paper
• Emerging pharmacological therapies in schizophrenia: what’s new, what’s different, what’s next?

  2016cites this paper
• Improving Current Treatments for Schizophrenia

  2016cites this paper
• Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone

  year unknowncites this paper